erythromycin has been researched along with Prosthesis Durability in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czarnetzki, C; Frossard, JL; Nawabi, S; Plojoux, J | 1 |
| Blasier, R; Markel, D; Peng, X; Ren, W; Shi, T; Wooley, PH | 1 |
| Qin, L; Zhang, P | 1 |
| Hawkins, M; Markel, DC; Ren, W; Shi, T; Zhang, R | 1 |
| Markel, DC; Ren, W | 1 |
| Oo, C; Shah, B | 1 |
| Chen, BD; Li, XH; Ren, W; Wooley, PH | 1 |
| Chen, BD; Mayton, L; Peng, X; Ren, J; Ren, W; Wooley, PH; Wu, B; Yu, D | 1 |
1 review(s) available for erythromycin and Prosthesis Durability
| Article | Year |
|---|---|
Potential use of erythromycin to prevent and treat prosthetic failure.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Erythromycin; Humans; Joint Prosthesis; Osteoclasts; Osteolysis; Prosthesis Failure; Prosthesis-Related Infections | 2010 |
1 trial(s) available for erythromycin and Prosthesis Durability
| Article | Year |
|---|---|
Effect of oral erythromycin therapy in patients with aseptic loosening of joint prostheses.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Cytokines; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Erythromycin; Female; Gene Expression; Gene Expression Profiling; Humans; Immunohistochemistry; Inflammation; Joint Prosthesis; Leukocytes, Mononuclear; Male; Middle Aged; Osteolysis; Osteoprotegerin; Prosthesis Failure; RANK Ligand; Reoperation; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
6 other study(ies) available for erythromycin and Prosthesis Durability
| Article | Year |
|---|---|
Endoscopic control of gastric emptying after administration of intravenous erythromycin in an awake patient scheduled for urgent rigid bronchoscopy.
Topics: Bronchoscopy; Device Removal; Endoscopy; Erythromycin; Gastric Emptying; Gastrointestinal Agents; Humans; Injections, Intravenous; Male; Middle Aged; Prosthesis Failure; Respiratory Insufficiency; Stents; Wakefulness | 2019 |
Efficacy of periprosthetic erythromycin delivery for wear debris-induced inflammation and osteolysis.
Topics: Animals; Anti-Bacterial Agents; Coated Materials, Biocompatible; Erythromycin; Humans; Implants, Experimental; Inflammation; Osteolysis; Polyethylenes; Prosthesis Failure; Rats; Rats, Sprague-Dawley; Tibia; Titanium | 2010 |
Emerging ideas: can erythromycin reduce the risk of aseptic loosening?
Topics: Animals; Anti-Inflammatory Agents; Arthroplasty, Replacement; Erythromycin; Inflammation; Joint Prosthesis; Models, Animal; Osteolysis; Prosthesis Failure; Rats; Reoperation | 2011 |
Does erythromycin have anti-inflammatory effects independent of its antimicrobial action?
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Erythromycin; Humans; Joint Prosthesis; Prosthesis Failure; Prosthesis-Related Infections | 2012 |
Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-kappaB activity.
Topics: Animals; Anti-Bacterial Agents; Bone Resorption; Carrier Proteins; Cell Line; Erythromycin; Gene Expression; Interleukin-1; Macrophages; Membrane Glycoproteins; Mice; NF-kappa B; Osteoclasts; Prosthesis Failure; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Skull; Tumor Necrosis Factor-alpha | 2004 |
Erythromycin inhibits wear debris-induced inflammatory osteolysis in a murine model.
Topics: Animals; Anti-Inflammatory Agents; Carrier Proteins; Disease Models, Animal; Erythromycin; Female; Inflammation; Injections, Intraperitoneal; Interleukin-1; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Osteolysis; Prosthesis Failure; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Skull; Tumor Necrosis Factor-alpha | 2006 |